Holistick Medical is an early-stage company developing an innovative device aimed at treating common cardiac defects, such as Patent Foramen Ovale (PFO), which can be linked to occurrence of stroke in young individuals. PFO is a septal defect, causing blood flow between left and right atria, and can be found in 25% of the population – in most cases without any impact on the individual’s health. Several recent clinical studies have shown a significant reduction of recurring stroke after PFO closure. Unlike current metallic devices, Holistick uses flexible and bioresorbable materials, allowing an atraumatic, small footprint PFO closure while leaving the septum intact.
This has the potential to improve long-term patient outcomes and provides options for future therapies.